Nov. 29, 2018—Roche announced the worldwide launch of the Ventana pan-TRK (EPR17341) Assay, an automated in vitro diagnostic immunohistochemistry assay to detect tropomyosin receptor kinase proteins in cancer. The CE IVD/U.S. class I assay is designed to detect C-terminal protein expression, which allows for the detection of TRK-fusion as well as wild-type protein expression.
“As the first test of its kind, the Ventana pan-TRK (EPR17341) Assay provides an important new tool to help us better understand the role of TRK protein expression, particularly fusions in cancer,” Jill German, head of Roche tissue diagnostics, said in a press release. “We are excited to see the new information that results from the use of this important technology, and its ultimate impact for patients.”
The assay is available for use on the company’s BenchMark series of IHC/ISH automated staining instruments.